mTOR Cancer Research Results

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
Scientific Papers found: Click to Expand⟱
1458- SFN,    Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
- Review, Bladder, NA
HDAC↓, eff↓, TumW↓, TumW↓, angioG↓, *toxicity↓, GutMicro↝, AntiCan↑, ROS↑, MMP↓, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8∅, cl‑PARP↑, TRAIL↑, DR5↑, eff↓, NRF2↑, ER Stress↑, COX2↓, EGFR↓, HER2/EBBR2↓, ChemoSen↑, NF-kB↓, TumCCA?, p‑Akt↓, p‑mTOR↓, p70S6↓, p19↑, P21↑, CD44↓, CSCs↓,
1479- SFN,    Sulforaphane triggers Sirtuin 3-mediated ferroptosis in colorectal cancer cells via activating the adenosine 5'-monophosphate (AMP)-activated protein kinase/ mechanistic target of rapamycin signaling pathway
- in-vitro, CRC, HCT116
Ferroptosis↑, SIRT3↑, AMPK↑, mTOR↑, tumCV↓, ROS↑, MDA↑, Iron↑,
1475- SFN,  Form,    Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway
- in-vitro, Cerv, HeLa
TumCP↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↑,
1513- SFN,  acetaz,    Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis
- in-vitro, BrCC, H720 - in-vivo, BrCC, NA - in-vitro, BrCC, H727
eff↑, tumCV↓, Apoptosis↑, P21↑, PI3K↓, Akt↓, mTOR↓, 5HT↓, NRF2↑,
4203- SIL,    Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders
- Review, NA, NA
*MAPK↝, *AMPK↝, *NF-kB↓, *mTOR↝, *PI3K↝, *Akt↝, *BioAv↝, *memory↑, *BDNF↑, *TNF-α↓,
3318- SIL,    Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight
- Review, AD, NA - Review, Park, NA
*hepatoP↑, *neuroP↑, *TLR4↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *memory↑, *cognitive↑, *NRF2↑, *HO-1↑, *ROS↓, *Akt↑, *mTOR↑, *SOD↑, *Catalase↑, *GSH↑, *IL10↑, *IL6↑, *NO↓, *MDA↓, *AChE↓, *MAPK↓, *BDNF↑,
3289- SIL,    Silymarin: a promising modulator of apoptosis and survival signaling in cancer
- Review, Var, NA
*BioAv↝, *BioAv↓, Fas↑, FasL↑, FADD↑, pro‑Casp8↑, Apoptosis↑, DR5↑, Bcl-2↑, BAX↑, Casp3↑, PI3K↓, FOXM1↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, Akt↑, angioG↓, STAT3↓, NF-kB↓, lipid-P↓, eff↑, CDK1↓, survivin↓, CycB/CCNB1↓, Mcl-1↓, Casp9↑, AP-1↓, BioAv↑,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓, Apoptosis↑, Casp3↑, PARP↑, TumCG↓,
2415- SK,    Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways
- in-vivo, Arthritis, NA
Apoptosis?, TumAuto↑, ROS↑, ATP↓, Glycolysis↓, PI3K↓, Akt↓, mTOR↓, *Apoptosis↓, *Inflam↓, *TNF-α↓, *IL6↓, *IL8↓, *IL10↓, *IL17↓, *hepatoP↑, *RenoP↑, PKM2↓, GLUT1↓, HK2↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2199- SK,    Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis
- in-vitro, GC, NA
ROS↑, lipid-P↑, Iron↑, MDA↑, GPx4↓, Ferritin↓, DLEU1↓, mTOR↓, Ferroptosis↑,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2224- SK,    Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
PYCR1↓, PI3K↓, Akt↓, mTOR↓, eff↑,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
5103- SK,    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor
- in-vitro, NSCLC, A549
CSCs↓, TumCP↓, Nanog↓, OCT4↓, p‑Akt↓, P70S6K↓, PI3K↓, mTOR↓, eff↑,
5081- SSE,    Application Notes and Protocols: Selenite as a Selenium Source in Cell Culture Media Supplementation
- Review, Var, NA
Dose↝, ROS↑, Akt↓, mTOR↓, TumCCA↑, Apoptosis↑,
5331- TFdiG,    Anti-Cancer Properties of Theaflavins
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, cl‑PARP↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, BAX↑, Bcl-2↓, p‑Akt↓, p‑mTOR↓, PI3K↓, cMyc↓, P53↑, ROS↑, NF-kB↓, MMP9↓, MMP2↓, TumVol↓, PSA↓, TumCCA↑, VEGF↓, Hif1a↓, CDK2↓, CDK4↓, GSH↓, Dose↑, BioAv↓, BioAv↓, BioAv↑,
3405- TQ,  doxoR,    Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity and the underlying mechanism
- vitro+vivo, NA, NA
*cardioP↑, *NRF2↑, *HO-1↑, *ROS↓, *NQO1↑, *COX2↓, *NOX4↓, *GPx4↑, *FTH1↑, *p‑mTOR↓, *TGF-β↓,
3411- TQ,    Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone
- Review, Var, NA
p‑STAT3↓, cycD1/CCND1↓, JAK2↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MET↓, p‑Akt↓, p‑mTOR↓, CXCR4↓, Bcl-2↓, BAX↑, ROS↑, Cyt‑c↑, Twist↓, Zeb1↓, E-cadherin↑, p‑p38↑, p‑MAPK↑, ERK↑, eff↑, ERK↓, TumCP↓, TumCMig↓, TumCI↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3425- TQ,    Advances in research on the relationship between thymoquinone and pancreatic cancer
Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, ChemoSen↑, angioG↓, Inflam↓, NF-kB↓, PI3K↓, Akt↓, TGF-β↓, Jun↓, p38↑, MAPK↑, MMP9↓, PKM2↓, ROS↑, JNK↑, MUC4↓, TGF-β↑, Dose↝, FAK↓, NOTCH↓, PTEN↑, mTOR↓, Warburg↓, XIAP↓, COX2↓, Casp9↑, Ki-67↓, CD34↓, VEGF↓, MCP1↓, survivin↓, Cyt‑c↑, Casp3↑, H4↑, HDAC↓,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, eff↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
5022- UA,    Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks
- Review, Var, NA
TumCP↓, Apoptosis↑, angioG↑, TumMeta↓, BioAv↓, Hif1a↓, Glycolysis↓, mitResp↓, Akt↓, MAPK↓, ERK↓, mTOR↓, P53↑, P21↑, E2Fs↑, STAT3↓, MMP↓, NLRP3↓, iNOS↓, CHK1↓, Chk2↓, BRCA1↓, E-cadherin↑, N-cadherin↓, Casp↑, p62↓, LC3II↑, Vim↓, ROS↑, CSCs↓, DNAdam↑, GutMicro↑, VEGF↓,
4869- Uro,    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*MitoP↑, *Inflam↓, *antiOx↑, *Risk↓, *Aβ↓, *p‑tau↓, *p62↓, *PARK2↑, *MMP↑, *ROS↓, *Strength↑, *CRP↓, *IL1β↓, *IL6↓, *TNF-α↓, *AMPK↑, *NF-kB↓, *MAPK↓, *p62↑, *NRF2↑, *SOD↑, *Catalase↑, *HO-1↑, *Ferroptosis↓, *lipid-P↓, *Cartilage↑, *PI3K↓, *Akt↓, *mTOR↓, *Apoptosis↓, *neuroP↑, *Bcl-2↓, *BAX↑, *Casp3↑, *ATP↑, *eff↑, *motorD↑, *NLRP3↓, *radioP↑, *BBB↑,
4864- Uro,    Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease
- Review, AD, NA
*neuroP↑, *Half-Life↝, *BBB↑, *toxicity↓, *Inflam↓, *Strength↑, *BACE↓, *Aβ↓, *MitoP↑, *SIRT1↑, *SIRT3↑, *AMPK↑, *PGC-1α↑, *mTOR↓, *PARK2↑, *Beclin-1↑, *ROS↓, *GutMicro↑, *Risk↓,
4860- Uro,    Urolithins–gut Microbial Metabolites with Potential Health Benefits
- Review, Nor, NA - Review, AD, NA - Review, Park, NA
*ROS↓, *Inflam↓, TumCG↓, *neuroP↑, *cardioP↑, *LDL↓, *BioAv↝, *BioAv↓, *BioAv↑, *SIRT1↑, *mTOR↑, *BDNF↑, *cognitive↑,
4835- Uro,    Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway
- in-vitro, SCC, NA
TumCD↑, ER Stress↑, Akt↓, mtDam↓, p‑mTOR↓, *BioAv↝, ROS↑, TumCCA↑, Apoptosis↑, ERK↓,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
3145- VitC,    Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose‐induced oncogenic effect by downregulating the Warburg effect
- in-vitro, CRC, HCT116
Warburg↓, TumCG↓, Glycolysis↓, GlucoseCon↓, ATP↓, lactateProd↓, selectivity↑, GLUT1↓, PKM2↓, LDHA↓, mTOR↓,
2366- VitD3,    Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells
- in-vitro, BC, MCF-7
Glycolysis↓, tumCV↓, Apoptosis↑, mTOR↓, AMPK↑, EMT↓, E-cadherin↑, F-actin↑, Vim↓,
2365- VitD3,    Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H1975 - in-vivo, NA, NA
Glycolysis↓, Warburg↓, GLUT1↓, LDHA↓, HK2↓, PKM2↓, OCT4↓, SOX2↓, Nanog↓, PI3K↓, Akt↓, mTOR↓,
2425- γ-Toc,    Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis
- in-vitro, NA, MCF-7 - in-vivo, NA, NA
TumCG↓, GlucoseCon↓, ATP↓, lactateProd↓, Glycolysis↓, HK2↓, PFK↓, PKM2↓, LDHA↓, Akt↓, p‑mTOR↓, cMyc↓,

Showing Research Papers: 251 to 288 of 288
Prev Page 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 288

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 2,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 1,   Iron↑, 2,   lipid-P↓, 2,   lipid-P↑, 1,   MDA↑, 2,   NRF2↓, 1,   NRF2↑, 2,   PYCR1↓, 1,   ROS↓, 1,   ROS↑, 17,   ROS⇅, 4,   SIRT3↑, 1,   TrxR1↓, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 3,   CDC2↓, 1,   CDC25↓, 1,   MEK↓, 2,   mitResp↓, 1,   MMP↓, 4,   mtDam↓, 1,   Raf↓, 2,   XIAP↓, 4,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 4,   ATG7↑, 1,   cMyc↓, 6,   GlucoseCon↓, 2,   Glycolysis↓, 6,   HK2↓, 3,   lactateProd↓, 2,   LDHA↓, 3,   PFK↓, 1,   PKM2↓, 7,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   Warburg↓, 3,  

Cell Death ⓘ

Akt↓, 17,   Akt↑, 1,   p‑Akt↓, 7,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 15,   ATF2↓, 1,   BAX↑, 8,   Bax:Bcl2↑, 1,   Bcl-2↓, 10,   Bcl-2↑, 2,   Bcl-xL↓, 3,   BID↓, 1,   BIM↓, 1,   Casp↑, 4,   Casp3↑, 10,   cl‑Casp3↑, 2,   Casp7↑, 3,   cl‑Casp7↑, 1,   Casp8↑, 1,   Casp8∅, 1,   cl‑Casp8↑, 2,   pro‑Casp8↑, 1,   Casp9↑, 7,   cl‑Casp9↑, 1,   Chk2↓, 1,   Cyt‑c↑, 4,   DR5↑, 3,   FADD↑, 1,   Fas↑, 2,   FasL↑, 1,   Ferroptosis↑, 2,   GRP58↓, 1,   IAP1↓, 1,   IAP2↑, 1,   iNOS↓, 2,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 2,   MAPK↑, 2,   p‑MAPK↑, 1,   Mcl-1↓, 3,   MDM2↑, 1,   Myc↓, 2,   Necroptosis↑, 1,   p27↑, 2,   p38↑, 3,   p‑p38↑, 2,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 7,   Telomerase↓, 1,   TRAIL↑, 3,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,   HER2/EBBR2↓, 1,   p70S6↓, 2,   p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

DLEU1↓, 1,   EZH2↓, 1,   H4↑, 1,   HATs↑, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

eIF2α↓, 2,   ER Stress↑, 2,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3I↑, 1,   LC3II↑, 3,   p62↓, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

BRCA1↓, 1,   CHK1↓, 1,   CYP1B1↑, 1,   DFF45↓, 1,   DNAdam↑, 2,   DNMT1↓, 3,   p16↑, 1,   P53↑, 7,   p53 Wildtype↑, 1,   PARP↑, 1,   cl‑PARP↑, 8,   PCNA↓, 1,   UHRF1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 6,   E2Fs↓, 1,   E2Fs↑, 1,   p19↑, 1,   P21↓, 1,   P21↑, 5,   TumCCA?, 1,   TumCCA↓, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 1,   CD34↓, 1,   CD44↓, 1,   cMET↓, 1,   CSCs↓, 3,   EMT↓, 7,   ERK↓, 7,   ERK↑, 1,   p‑ERK↓, 1,   FOXM1↓, 1,   FOXO↑, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   HDAC↓, 4,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HH↓, 1,   IGF-1↓, 1,   Jun↓, 1,   miR-34a↑, 1,   mTOR↓, 24,   mTOR↑, 2,   p‑mTOR↓, 6,   Nanog↓, 2,   NOTCH↓, 3,   OCT4↓, 2,   P70S6K↓, 2,   p‑P70S6K↓, 1,   PI3K↓, 17,   PTEN↑, 6,   RAS↓, 1,   SOX2↓, 1,   Src↓, 2,   STAT3↓, 5,   p‑STAT3↓, 2,   TumCG↓, 5,   Wnt↓, 2,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 2,   Ca+2↑, 1,   CD31↓, 1,   DLC1↑, 1,   E-cadherin↓, 1,   E-cadherin↑, 5,   F-actin↑, 1,   FAK↓, 3,   GLI2↓, 1,   ITGA5↓, 1,   Ki-67↓, 2,   MET↓, 1,   MMP13↓, 1,   MMP2↓, 3,   MMP7↓, 3,   MMP9↓, 6,   MMPs↓, 3,   MUC4↓, 2,   N-cadherin↓, 4,   Rac1↓, 1,   RIP3↓, 1,   RIP3↑, 1,   Slug↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TGF-β↑, 1,   Treg lymp↓, 1,   TumCI↓, 4,   TumCMig↓, 6,   TumCP↓, 10,   TumMeta↓, 4,   Twist↓, 5,   uPA↓, 2,   Vim↓, 5,   Zeb1↓, 3,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   angioG↑, 2,   EGFR↓, 1,   Hif1a↓, 6,   TAMS↓, 1,   VEGF↓, 9,   VEGFR2↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 3,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 7,   CXCL1↓, 1,   CXCR4↓, 3,   IFN-γ↑, 1,   IL1↓, 1,   IL10↓, 2,   IL12↓, 1,   IL1β↓, 1,   IL2↑, 2,   IL6↓, 2,   Inflam↓, 4,   IκB↓, 1,   JAK2↓, 3,   MCP1↓, 1,   MDSCs↓, 1,   NF-kB↓, 10,   p‑NF-kB↑, 1,   p65↓, 2,   p‑p65↓, 1,   PSA↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 5,   BioAv↝, 1,   ChemoSen↑, 7,   Dose↑, 1,   Dose↝, 2,   eff↓, 2,   eff↑, 10,   Half-Life↝, 2,   MDR1↓, 1,   RadioS↑, 4,   selectivity↑, 5,   TET2↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 2,   BRCA1↓, 1,   EGFR↓, 1,   EZH2↓, 1,   Ferritin↓, 1,   FOXM1↓, 1,   GutMicro↑, 1,   GutMicro↝, 1,   HER2/EBBR2↓, 1,   IL6↓, 2,   Ki-67↓, 2,   Myc↓, 2,   NOS2↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   cardioP↑, 1,   chemoP↑, 3,   chemoPv↑, 1,   hepatoP↑, 2,   neuroP↑, 1,   OS↑, 2,   TumVol↓, 2,   TumW↓, 2,  
Total Targets: 284

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 4,   Ferroptosis↓, 1,   GPx↑, 2,   GPx4↑, 1,   GSH↑, 2,   GSTA1↑, 1,   HO-1↑, 3,   lipid-P↓, 1,   MDA↓, 2,   NOX4↓, 1,   NQO1↑, 1,   NRF2↑, 3,   PARK2↑, 2,   ROS↓, 6,   SIRT3↑, 1,   SOD↑, 4,  

Metal & Cofactor Biology ⓘ

FTH1↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   MMP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 2,   AMPK↝, 1,   LDL↓, 1,   NAD↑, 1,   SIRT1↑, 3,  

Cell Death ⓘ

Akt↓, 1,   Akt↑, 1,   Akt↝, 1,   Apoptosis↓, 2,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Ferroptosis↓, 1,   MAPK↓, 2,   MAPK↝, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   MitoP↑, 2,   p62↓, 1,   p62↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 2,   mTOR↑, 2,   mTOR↝, 1,   p‑mTOR↓, 1,   PI3K↓, 1,   PI3K↝, 1,  

Migration ⓘ

Cartilage↑, 1,   MMP13↓, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Barriers & Transport ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CRP↓, 2,   IL10↓, 1,   IL10↑, 1,   IL17↓, 1,   IL1β↓, 4,   IL6↓, 3,   IL6↑, 1,   IL8↓, 1,   Inflam↓, 6,   NF-kB↓, 3,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 5,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 3,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,   BACE↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 2,   BioAv↝, 6,   eff↑, 2,   Half-Life↝, 3,  

Clinical Biomarkers ⓘ

CRP↓, 2,   GutMicro↑, 1,   IL6↓, 3,   IL6↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   chemoPv↑, 1,   cognitive↑, 2,   hepatoP↑, 3,   memory↑, 2,   motorD↑, 1,   neuroP↑, 4,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 2,   Strength↑, 2,   toxicity↓, 3,  
Total Targets: 92

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
17 Curcumin
14 Berberine
14 Quercetin
13 Baicalein
12 Fisetin
9 Thymoquinone
8 Apigenin (mainly Parsley)
8 Magnetic Fields
8 Honokiol
8 Resveratrol
8 Shikonin
7 Alpha-Lipoic-Acid
7 Artemisinin
7 EGCG (Epigallocatechin Gallate)
6 diet FMD Fasting Mimicking Diet
6 Lycopene
6 Sulforaphane (mainly Broccoli)
6 Urolithin
5 Chemotherapy
5 Magnolol
5 Piperlongumine
5 Rosmarinic acid
5 Silymarin (Milk Thistle) silibinin
4 Ashwagandha(Withaferin A)
4 Citric Acid
4 Metformin
4 Piperine
4 Pterostilbene
3 5-fluorouracil
3 Coenzyme Q10
3 Astragalus
3 Cisplatin
3 brusatol
3 Capsaicin
3 Chrysin
3 salinomycin
3 diet Short Term Fasting
3 Gambogic Acid
3 Hydrogen Gas
3 Magnetic Field Rotating
3 Naringin
2 Auranofin
2 Silver-NanoParticles
2 Allicin (mainly Garlic)
2 Betulinic acid
2 Brucea javanica
2 Boswellia (frankincense)
2 Propolis -bee glue
2 Ursolic acid
2 Dichloroacetate
2 Deguelin
2 Ellagic acid
2 HydroxyTyrosol
2 itraconazole
2 Juglone
2 Luteolin
2 Niclosamide (Niclocide)
2 doxorubicin
2 Plumbagin
2 Vitamin D3
1 Andrographis
1 2-DeoxyGlucose
1 Baicalin
1 Biochanin A
1 Bufalin/Huachansu
1 Butyrate
1 Carnosic acid
1 Trastuzumab
1 Crocetin
1 diet Methionine-Restricted Diet
1 Emodin
1 Ferulic acid
1 flavonoids
1 Garcinol
1 HydroxyCitric Acid
1 Huperzine A/Huperzia serrata
1 Ivermectin
1 Sorafenib (brand name Nexavar)
1 Laetrile B17 Amygdalin
1 Methylene blue
1 MCToil
1 Oleuropein
1 Oleocanthal
1 sericin
1 Phenethyl isothiocyanate
1 Parthenolide
1 Gold NanoParticles
1 Selenium
1 Selenium NanoParticles
1 Formononetin
1 acetazolamide
1 Selenite (Sodium)
1 Aflavin-3,3′-digallate
1 Vitamin C (Ascorbic Acid)
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:209  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page